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Summary An immunotoxin (IT) comprising abrin A chain attached to the mouse monoclonal antibody SWAl 1, recognising a cell surface antigen highly associated with human small cell lung cancer (SCLC), was synthesised using a hindered disulphide crosslinker, N-succinimidyl 3-(2-pyridyldithio) butyrate (SPDB), and purified by Blue Sepharose CL-6B affinity chromatography. The IT preparation contained monomeric conjugate, composed of one abrin A chain molecule linked to one SWAlI1 molecule, and was free from unconjugated A chain or antibody. The IT fully retained the cell-binding capacity of the antibody component and the ribosome-inactivating activity of the A chain. In cytotoxicity assays using the SW2 SCLC cell line in tissue culture, SWA I-SPDB-abrin A chain inhibited the incorporation of 3H-leucine by 50% at a concentration of 10 pM and by 99% at a concentration of 1 nM. The anti-tumour Wawrzynczak, 1991) . Three innovations in IT production have been introduced to improve IT efficacy. Firstly, the use of toxin A chains that lack oligosaccharide side-chains or that contain chemically-modified carbohydrate structures to prevent liver entrapment (Thorpe et al., 1988; Wawrzynczak et al., 1990a Wawrzynczak et al., , 1991a . Secondly, the use of hindered disulphide linkages to increase IT stability in the circulation (Worrell et al., 1986; Thorpe et al., 1988) . Thirdly, the affinity purification of IT by Blue Sepharose chromatography to remove unconjugated antibody (Knowles & Thorpe, 1987) .
The A chain of the toxin abrin, which resembles ricin in structure and mode of action, possesses properties that make it attractive for the construction of therapeutic ITs. Firstly, abrin A chain occurs naturally in a form devoid of side-chain glycosylation and consequently abrin A chain ITs are subject to only a low level of hepatic uptake in vivo (Olsnes et al., 1975; Skilleter et al., 1989) . Secondly, abrin A chain ITs have a greater intrinsic resistance to breakdown in vitro and in vivo than ricin A chain ITs (Wawrzynczak et al., 1990a) . Thirdly, abrin A chain forms ITs with a potency matching or exceeding that of analogous ITs made using ricin A chain (Forrester et al., 1984; Blakey et al., 1987; Sivam et al., 1987 (Hwang et al., 1984; Blakey et al., 1987; .
The mouse Mab SWA11, recognising a cell-surface antigen highly associated with human small cell lung cancer (SCLC), has been shown to localise efficiently in xenografts of the SCLC cell line SW2 in nude mice (Smith et al., 1989; 1990; 1991) and to form A chain ITs with selective toxic activity against several SCLC cell lines in tissue culture (Wawrzynczak et al., 1990b; 1991b) . In this study, we have synthesised, affinity purified, and fully characterised an IT 
Materials and methods
Synthesis and purification of immunotoxins SWAI 1 (mouse IgG2a) was purified from hybridoma supernatant as described by Smith et al. (1989) . Abrin A chain was purified from the native abrin toxin as described by Wawrzynczak et al. (1990a) . N-succinimidyl-3-(2-pyridyldithio) butyrate (SPDB) was synthesised according to Worrell et al. (1986) . SWA1 l-SPDB-abrin A chain was synthesised following the basic methodology described by Cumber et al. (1985) with a number of important modifications. SWAI1 (50 mg) was subjected to affinity chromatography on a column (50 cm x 1.6 cm i.d.) of Blue Sepharose CL-6B equilibrated with 50 mM sodium phosphate buffer, pH 7.5 (Knowles & Thorpe, 1987 from the column. The IT fraction, all of which bound to the column, was removed with phosphate buffer containing 1 M NaCl, concentrated, and dialysed into phosphate-buffered saline (PBS). The final preparation of SWAl l-SPDB-abrin A chain at a concentation of 0.50 mg IT ml-' was sterilised by filtration, aliquoted into sterile Nunc vials in a laminar flow cabinet, frozen rapidly in liquid N2, and stored at -70°C.
An IT comprising abrin A chain conjugated to SWAl 1 via the conventional unhindered disulphide crosslinker N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP) was prepared as described previously (Forrester et al., 1984; Wawrzynczak et al., 1990b) .
Molecular properties of SWAII-SPDB-abrin A chain Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and gel permeation high performance liquid chromatography (HPLC) were performed as described previously (Wawrzynczak et al., 1990a ).
Ribosome-inactivating activity was determined using a rabbit reticulocyte lysate assay similar to that described by Forrester et al. (1984) . Samples of IT or abrin toxin were pre-treated with 2-mercaptoethanol at a final concentration of 0.2 M for 1 h at 37°C to generate free A chain for the assay.
Cell-binding ability was measured by indirect immunofluorescence essentially as described by Derbyshire and Wawrzynczak (1991) . Briefly, a total of 1 x 106 SW2 cells, preincubated with IT or unconjugated SWAl 1 at various concentrations on ice, were treated with anti-mouse Ig, fluorescein-linked whole antibody from sheep and analysed by flow cytometry.
Cytotoxic effects of immunotoxins Cytotoxic activity against the SW2 cell line in tissue culture was determined essentially as described by Wawrzynczak et al. (1990b) . Briefly, dilutions of ITs or other agents were added to microtitre wells containing a total of 2 x 104 SW2 cells in suspension and incubated for 48 h. 3H-Leucine (1 pCi) was added to each culture followed by incubation for a further 24 h, harvesting of cells, and measurement of cellincorporated radioactivity by scintillation counting.
Toxicity of SWAII-SPDB-abrin A chain to nude mice Male nu/nu mice received a single i.p. injection of the sterile stock solution of SWAI1-SPDB-abrin A chain at each of four doses, 15, 30, 60 and 120 fig IT per mouse, or abrin A chain at 100, 200, 400 and 800 fg per mouse. The animals were monitored at intervals for evidence of toxic signs and weight loss, and were killed painlessly at the onset of moribundity. The mean weight of the mice at the start of the experiment were 19.3 g ( ± 0.8 g) and 18.8 g ( ± 1.3 g) for the groups treated with the IT and A chain respectively. The LD50 doses were calculated according to Weil (1952) .
Therapy experiments in nude mice Stock solutions of SWA1 1-SPDB-abrin A chain, SWA 11 and abrin A chain in PBS were prepared for injection by dilution under sterile conditions. The final solutions contained IT at a concentration of 90 Atg ml-1, Mab at 75 jig ml-' and A chain at 15 tLg ml-'. S-carboxymethylated bovine serum albumin was included at 0.5 mg ml -as a carrier protein.
Groups of 6 to 8 nu/nu mice were implanted s.c. in one flank with a suspension of 1 x 107 SW2 cells from tissue culture. After approximately 2 to 3 weeks when tumours became palpable, each mouse received a single i.v. injection of 0.1 ml solution containing (i) IT, (ii) unconjugated Mab, (iii) unconjugated A chain, or (iv) carrier protein only. Tumour growth was monitored by measuring the two largest perpendicular diameters and calculating tumour volume according to the formula:
where d and D are the shorter and longer diameters respectively.
Results

Molecular properties of SWAJI -SPDB-abrin A chain
The affinity-purified preparation of SWAI1-SPDB-abrin A chain migrated on SDS-PAGE predominantly as a single band having a lower mobility than that of the unmodified SWAl 1 antibody (Figure 1 ). This electrophoretic behaviour was consistent with that expected of a conjugate comprised of a single molecule of abrin A chain (30 kDa) covalently linked to a single molecule of SWAl 1 (150 kDa). The IT preparation eluted from a gel permeation HPLC column as a single sharp peak with an elution time slightly shorter than that of SWA 11 itself (Figure 2 ). The elution time was consistent with the expected molecular mass of monomeric IT (180 kDa). The preparation was entirely free of aggregated protein which would have eluted at the void volume of the column.
The ability of SWAl l-SPDB-abrin A chain to associate with live SW2 cells was determined by indirect immunofluorescence and flow cytometry (Figure 3 ). Both the IT and unconjugated SWAl 1 bound to the cells in similar amounts at corresponding concentrations of Mab indicating that the binding ability of the Mab had not been significantly diminished by attachment of the A chain. The IT also retained the full ribosome-inactivating activity of the conjugated abrin A chain. Following reduction to generate the free A chain, the IT preparation had identical catalytic activity in a cell-free assay to native abrin toxin at equimolar concentration Cytotoxic effects of SWAIJ-SPDB-abrin A chain SWA 11-SPDB-abrin A chain caused a concentration-dependent inhibition of 3H-leucine incorporation by SW2 cells in tissue culture. The results of a representative experiment are shown in Figure 5 . The concentration at which 3H-leucine incorporation was inhibited by 50% (IC50) was 1.2 ± 0.6 x 10-11 M (mean and standard deviation calculated from three separate experiments). At an IT concentration of 1 x 10' M, 3H-leucine incorporation was decreased to less than 1% of that by untreated cells. The cytotoxic activity of the IT made with the hindred disulphide linker did not differ significantly from that of an analogous IT made with the standard unhindered linker, SWAl I-SPDE-abrin A chain, which had an IC50 of 0.8 ± 0.6 x 101-X M. SWA1 1-SPDB-abrin A chain was approximately 220-fold less toxic than abrin, with an IC50 of 5.4 ± 1.7 x 10-14 M and 160-fold more potent than unconjugated abrin A chain which had an IC50 of 1.9 ± 1.4 x 10-9 M. Unconjugated SWA 1I had no cytotoxic effects on SW2 cells at a concentration of 1 x 10-7 M. In control 10-14 10-13 10-12 10-11 110 i0-9 1o-8
Concentration of A chain (M) Figure 5 Cytotoxic effects of SWAI l-SPDB-abrin A chain. SW2 cells in tissue culture were treated with SWA 11 -SPDB-abrin A chain (0), SWA1 l-SPDP-abrin A chain (0) 5 fig) , or of the carrier protein solution alone. Treatment of mice with these agents at the doses stated produced no weight losses or other signs of toxicity. The effects of the treatments on tumour growth were monitored by measuring the relative increase in tumour volume (Figure 6a ). Tumour growth was not inhibited by abrin A chain alone compared to the treatment with carrier solution or untreated controls (omitted for clarity). The SWA 11 Mab alone gave a slight tumour growth delay of 2 days although this was not significantly different from the growth of tumours in mice receiving abrin A chain. In contrast, tumour-bearing mice treated with SWA1 1-SPDB-abrin A chain demonstrated a growth delay of 7 days relative to those treated with abrin A chain only which was significant by Student's t-test (P = 0.05-0.02).
For the groups of tumour-bearing mice treated with the IT or the A chain, the mean tumour volumes at the time of injection were 114 ± 37 mm3 and 116 ± 26 mm3 respectively.
Analysis of the data for the three mice in each of these two groups bearing the smallest tumours, 55 ± 4 mm3 and 54±9 mm3 for the IT and A chain respectively, revealed a more pronounced anti-tumour effect (Figure 6b ). Tumourbearing mice treated with IT showed no increase in tumour size in the 7 days following IT injection and a significant (P = 0.05-0.02) tumour growth delay averaging 10 days.
In a further experiment, tumour-bearing mice were treated with a single i.v. injection of carrier-free abrin A chain at a dose of 3.1 mg kg-' equivalent to 15% of the LD50 dose determined by i.p. administration of A chain. There was no significant difference in the growth rate of SW2 xenografts between groups of mice receiving the A chain or diluent alone. Thorpe et al., 1988) . The cytotoxic activity of the two SWAl 1-abrin A chain ITs was found to be identical to that of an analogous SWAl 1-SPDP-ricin A chain IT in parallel assays whereas abrin toxin and unconjugated abrin A chain were approximately 5-fold more toxic to the SW2 cell line than ricin and ricin A chain respectively (Derbyshire et al., unpublished results) . This suggests that the cytotoxic potency of the cell-binding ITs in this system was determined by the antigen-dependent route of entry into the target cell rather than by the inherent properties of the A chain.
The antigen-negative or IT-resistant cells or from failure to eradicate target antigen-positive cells because of insufficient IT penetration, and to define the optimal dosing schedules for achieving maximal anti-tumour effects.
In summary, we have demonstrated that a selectively cytotoxic SWAl 1-abrin A chain IT made with a hindered disulphide crosslinker was capable of inducing a significant delay in the growth of a solid SCLC tumour xenograft in a nude mouse model at a single non-toxic dose. This is the first report describing the anti-tumour effects of an anti-SCLC A chain IT in vivo. The findings of this study have two major implications. Firstly, abrin A chain appears to be highly suitable for the production of therapeutic ITs. The cloning of the abrin gene and the demonstration of the expression of the A chain from Escherichia coli in catalytically active form (Wood et al., 1991) will permit the further optimisation of the properties of abrin A chain ITs. Secondly, the antigen recognised by the SWAl1 Mab is an effective target for therapy of SCLC with A chain ITs. This antigen has recently been cloned and characterised (Waibel et al., unpublished results) enhancing the prospect of developing second generation anti-SCLC ITs with greater activity and selectivity.
